Identifying the Pathway to Successful Patient Care: Practical Implementation of Incretin-Based Therapies in Type 2 Diabetes 

Faculty
Derek LeRoith, MD, PhD – Chairperson
Chief, Division of Endocrinology, Diabetes and Bone Disease
Professor of Medicine
Mount Sinai School of Medicine
New York, New York

Stephen A. Brunton, MD, FAAFP, FRACGP
Executive Director
Primary Care Metabolic Group
Adjunct Professor, Department of Family Practice
University of North Carolina Charlotte
Charlotte, North Carolina

Javier Morales, MD
St. Francis Hospital
Advanced Internal Medicine Group
New Hyde Park, New York

Activity Overview
This activity is composed of 3 interactive case studies that explore the use of incretin-based therapies for addressing type 2 diabetes (T2D) disease pathophysiology as well as individualized treatment approaches. Glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are incretin-based therapies introduced in the last 5 years. GLP-1 receptor agonists and DPP-4 inhibitors address multiple pathophysiological defects of T2D and may be appropriate treatment options for many patients. Given the increasing abundance of data for these agents and recent treatment algorithm updates regarding their use, physicians and other healthcare providers (HCPs) who treat patients with diabetes are likely to benefit from examining strategies for implementing incretin-based therapies through several diverse clinical scenarios.

Intended Audience
This activity is intended for family physicians and other HCPs who treat patients with T2D.

Learning Objectives
Upon completion of this activity, the participant should be able to:

Learning Format
This online activity consists of 3 interactive case studies. After a brief review of each virtual patient’s medical history and current laboratory data, the participant will be asked to select an appropriate treatment strategy consistent with each patient. The benefits and limitations of each approach will be described in detail. Each question and its accompanying answer explanation must be reviewed before proceeding to the next case. Participants may pause between cases to make it easier to accommodate their busy schedules.

 

Accreditation and Credit Designation Statements 

For Physicians:
The Institute for Medical and Nursing Education, Inc (IMNE) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
 
IMNE designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity, Identifying the Pathway to Successful Patient Care: Practical Implementation of Incretin-Based Therapies in Type 2 Diabetes, with a beginning date of January 31, 2011, has been reviewed and is acceptable for up to 1.5 Prescribed credits by the American Academy of Family Physicians.
 
For Nurses: IMNE is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC’s) Committee on Accreditation.
 
IMNE designates this educational activity for 1.5 contact hours (0.15 CEUs). Accreditation by the ANCC’s Committee on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.
 
ANCC-accredited providers have been approved by the National Certification Board for Diabetes Educators (NCBDE) as providers of continuing education (CE). Individuals seeking recertification from the NCBDE can use the CE contact hours received through participation in this activity.

Disclosures
In compliance with the ACCME and American Nurses Credentialing Center (ANCC), it is the policy of IMNE to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in planning (eg, faculty, CME/CE provider staff, educational partner staff, and CME/CE reviewers) are expected to disclose any significant financial relationships with commercial interests over the past 12 months. IMNE also requires that faculty identify and reference off-label product or investigational uses of pharmaceutical agents and medical devices

In accordance with the ACCME Standards for Commercial Support, parallel documents from other accrediting bodies, and IMNE policy, identification and resolution of conflict of interest have been made in the form of external peer review of educational content.

The following disclosures have been made:

Faculty
Derek LeRoith, MD, PhD – Chairperson
Research Activities: Novartis; sanofi-aventis
Speakers Bureau: AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Merck & Co, Inc; sanofi-aventis
Consultant: AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Merck & Co, Inc; sanofi-aventis

Dr LeRoith has disclosed that he does not anticipate discussing off-label or investigational uses of any products.

Stephen A. Brunton, MD, FAAFP, FRACGP
Advisory Board: Amylin Pharmaceuticals, Inc; Kowa Pharmaceuticals America, Inc; Novo Nordisk Inc
Speakers Bureau: Boehringer Ingelheim; Novo Nordisk Inc

Dr Brunton has disclosed that he does not anticipate discussing off-label or investigational uses of any products.

Javier Morales, MD
Advisory Board: Novo Nordisk Inc
Speakers Bureau: Novo Nordisk Inc
Consultant: Novo Nordisk Inc

Dr Morales has disclosed that he does not anticipate discussing off-label or investigational uses of any products.

CME Provider and Educational Partner Staff
All staff of IMNE in a position to influence content have filed statements of disclosure with the CE provider. Any conflicts of interest were identified and resolved prior to their involvement in planning this activity. These disclosures are available for review by contacting Adelfo San Valentin at 404 443 1512 or adelfo.sanvalentin@imne.com.

Amy Carbonara
Director, Program Development
IMNE
Ms Carbonara has nothing to disclose.

Betsey King
Associate Director, Program Development
IMNE
Ms King has nothing to disclose.

Kim McFarland, PhD
Senior Medical Writer
IMNE
Stock Interests: Pfizer Inc; Procter & Gamble

Angela McIntosh, PhD
Scientific Director
IMNE
Dr McIntosh has nothing to disclose.

Adelfo San Valentin, MBA
Associate Director of CME
IMNE
Mr San Valentin has nothing to disclose.

Steve Weinman, RN
Executive Director
IMNE
Mr Weinman has nothing to disclose.

CME and CE Reviewers

Robert Hash, MD
Texas A&M Health Science Center
College of Medicine
College Station, Texas
Dr Hash has nothing to disclose.

Martin Quan, MD
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California
Dr Quan has nothing to disclose.

Editorial Acknowledgment
The faculty thanks the following individuals for their contributions to the content development of this educational activity: Kim McFarland, PhD, and Angela McIntosh, PhD. 

Disclaimer
This activity is designed for HCPs for educational purposes. Information and opinions offered by the faculty/presenters represent their own viewpoints. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information.

While IMNE makes every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Commercial Support Acknowledgment
This program is supported by an unrestricted educational grant from Novo Nordisk Inc.

Method of Participation
This enduring material is presented in an electronic format.
To receive a maximum of 1.5 AMA PRA Category 1 Credits™ participants should follow these instructions:

Minimum System Requirements

 The estimated time to complete all 3 cases in this activity, including review of material, is 1.5 hours.